碳青霉烯类耐药与新型冠状病毒肺炎相关。
Carbapenem-Resistant Associated with COVID-19.
作者信息
Dumitru Irina Magdalena, Dumitrascu Mirela, Vlad Nicoleta Dorina, Cernat Roxana Carmen, Ilie-Serban Carmen, Hangan Aurelia, Slujitoru Raluca Elena, Gherghina Aura, Mitroi-Maxim Corina, Curtali Licdan, Carp Dalia Sorina, Dumitrescu Anca, Mitan Romelia, Lesanu Rodica, Rugina Sorin
机构信息
Clinical Infectious Diseases Hospital, 100 Ferdinand Str, 900709 Constanta, Romania.
Faculty of Medicine, Ovidius University of Constanta, Aleea Universității, nr. 1, 900470 Constanta, Romania.
出版信息
Antibiotics (Basel). 2021 May 11;10(5):561. doi: 10.3390/antibiotics10050561.
Infections with carbapenem-resistant are emerging as an important challenge in healthcare settings. Currently, carbapenem-resistant (CRKP) are the species of CRE most commonly encountered in hospitals. CRKP is resistant to almost all available antimicrobial agents, and infections with CRKP have been associated with high rates of morbidity and mortality, particularly among persons with prolonged hospitalization exposed to invasive devices. We report nine patients hospitalized in an intensive care unit (ICU) with severe coronavirus disease 2019 (COVID-19) who developed invasive infections due to carbapenemase-producing (CP-Kp), KPC and OXA-48, strains that have not been previously identified in our hospital. Despite ceftazidime/avibactam therapy, five patients died. Coinfections can contribute to a poor prognosis for patients with COVID-19, especially for high-risk populations such as elderly patients. Therefore, it is crucial to establish a rigorous program of antibiotic administration in intensive care units.
耐碳青霉烯类感染正成为医疗机构中的一项重要挑战。目前，耐碳青霉烯类肺炎克雷伯菌（CRKP）是医院中最常遇到的产碳青霉烯酶肠杆菌科细菌（CRE）种类。CRKP对几乎所有可用的抗菌药物均耐药，且CRKP感染与高发病率和死亡率相关，尤其是在长时间住院且接触侵入性设备的人群中。我们报告了9例在重症监护病房（ICU）住院的患有严重2019冠状病毒病（COVID-19）的患者，他们因产碳青霉烯酶肺炎克雷伯菌（CP-Kp）、KPC和OXA-48菌株发生了侵袭性感染，这些菌株此前在我们医院尚未被识别。尽管接受了头孢他啶/阿维巴坦治疗，仍有5例患者死亡。合并感染会导致COVID-19患者预后不良，尤其是对于老年患者等高风险人群。因此，在重症监护病房建立严格的抗生素给药方案至关重要。
Zotero 插件